GlaxoSmithKline Abreva $10 Mil. Sales Help Offset Smoking Cessation Woes
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's Abreva posted $10 mil. in sales during the OTC cold sore medication's first full quarter on the U.S. market.
You may also be interested in...
Block Boosts GSK Consumer Group In Q2, Offsets NicoDerm, Nicorette Losses
GlaxoSmithKline's consumer healthcare sales rose 19% to $1.15 bil. in the second quarter due to the addition of Block Drug's OTC portfolio. Excluding Block revenue, sales declined 2%, largely reflecting the firm's faltering smoking cessation business.
Whitehall Dimetapp Reformulations, New Products Drive U.S. Growth
Whitehall-Robins' quick reformulation and shipment of PPA-free Dimetapp products spurred a 50.3% increase in the brand's domestic sales during the first quarter. Dimetapp sales reached $23.6 mil. in the U.S., compared to $15.7 mil. in the year-ago period, Whitehall parent American Home Products said April 25.
Abreva Shortened Healing Time, Duration Of Cold Sores Stressed In Promos
SmithKline Beecham's Abreva, now hitting shelves in food, drug and mass outlets, is the first OTC indicated for shortening the healing time and duration of symptoms related to cold sores and fever blisters.